ProfileGDS5678 / 1421920_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 42% 42% 60% 43% 41% 40% 42% 41% 42% 42% 40% 42% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0043342
GSM967853U87-EV human glioblastoma xenograft - Control 22.9709542
GSM967854U87-EV human glioblastoma xenograft - Control 32.9737242
GSM967855U87-EV human glioblastoma xenograft - Control 43.5333260
GSM967856U87-EV human glioblastoma xenograft - Control 52.9420543
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0326941
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9903940
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9530142
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9291641
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9544842
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9529242
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8951140
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9685442
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9552642